PERFIL EPIDEMIOLÓGICO E TENDÊNCIA DA MORTALIDADE POR CÂNCER DE PRÓSTATA NO BRASIL E SUAS REGIÕES DE 2012 A 2021

Lucas Gomes Dantas; Ana Helena Prado Santana Campos; Yvnna Santos Lima; Júlia Santos de Almeida Barretto; José Monteiro Sobral Neto; Vitor Alcantara Lopes Pionorio; Jefferson Felipe Calazans Batista; Sonia Oliveira Lima

doi:10.36489/saudecoletiva.2024v14i90p13412-13422

Authors

Lucas Gomes Dantas Acadêmico de Medicina. https://orcid.org/0009-0002-1982-5865
Ana Helena Prado Santana Campos Acadêmica de Medicina. https://orcid.org/0009-0005-0284-2281
Yvnna Santos Lima Acadêmico de Medicina https://orcid.org/0000-0002-6698-2284
Júlia Santos de Almeida Barretto Acadêmica de Medicina https://orcid.org/0000-0001-9108-2002
José Monteiro Sobral Neto Acadêmico de Medicina. https://orcid.org/0000-0003-1438-2196
Vitor Alcantara Lopes Pionorio Acadêmico de Medicina. https://orcid.org/0009-0000-9239-8578
Jefferson Felipe Calazans Batista Doutorando e Mestre em Saúde e Ambiente https://orcid.org/0000-0002-3681-7990
Sonia Oliveira Lima Doutora e Mestra em Clínica Cirúrgica https://orcid.org/0000-0002-3257-2412

DOI:

https://doi.org/10.36489/saudecoletiva.2024v14i90p13412-13422

Keywords:

Prostate cancer; Mortality; Risk factors; Health profile; Epidemiological profile of ethnic groups

Abstract

Objective: To analyze the temporal trend of prostate cancer mortality in the country and macro-regions from 2012 to 2021. Methods: This is an ecological, descriptive and exploratory study of prostate cancer in Brazil from 2012 to 2021. Standardized mortality rates (SMR) were calculated. The time trend was stipulated by Prais-Winsten regression. Results: The highest PMR averages in Brazil were for the Midwest region with 61.70 deaths per 100,000 men (standard deviation - SD=4.25), followed by the Northeast with 60.71 deaths/100,000 (SD=1.77). The Midwest region had an annual percentage change (APC) between 55-59 years of -5.07% (95% confidence interval - 95%CI = -8.44; -1.57), while in the Northeast it was -1.75% (95%CI = -2.43; -1.05). The indigenous race in Brazil had a PAV of 5.58% (95%CI = 1.35; 10.03). Conclusion: The temporal trend in the Midwest and Northeast between 55-59 years of age was downward in Brazil, while mortality in the indigenous race in Brazil pattern was upward.

References

Instituto Nacional do Câncer. Incidência de câncer no Brasil, https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa2020. pdf. (2024, accessed 1 April 2024).

Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019; 10: 63–89.

Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Mol Basel Switz 2022; 27: 5730.

World Health Organization. Prostate cancer, https://platform.who.int/mortality/themes/theme- details/topics/indicatorgroups/indicator-group-details/MDB/prostate-cancer (2024, accessed 1 April 2024).

Brasil. Câncer de próstata, https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a- z/c/cancer-deprostata#:~:text=Hist%C3%B3rico%20de%20c%C3%A2ncer%20na%20fam%C3% ADlia (2024, accessed 1 April 2024).

Instituto Brasileiro de Geografia e Estatística. Projeção da população do Brasil e das Unidades da Federação. IBGE, https://www.ibge.gov.br/apps/populacao/projecao/index.html (2021, accessed 18 October 2021).

Naing NN. Easy Way to Learn Standardization : Direct and Indirect Methods. Malays J Med Sci MJMS 2000; 7: 10–15.

Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age Standardization of Rates: A new WHO Standard.

Antunes JLF, Cardoso MRA. Uso da análise de séries temporais em estudos epidemiológicos. Epidemiol E Serviços Saúde 2015; 24: 565–576.

Ng KL. The Etiology of Prostate Cancer. In: Bott SR, Ng KL (eds) Prostate Cancer. Brisbane (AU): Exon Publications, http://www.ncbi.nlm.nih.gov/books/NBK571322/ (2021, accessed 1 April 2024).

Silva JFS da, Mattos IE, Aydos RD. Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980 - 2011. Rev Bras Epidemiol 2014; 17: 395–406.

Costa YXA, Duarte TC, Silva-Barbosa CE da, Neto BHM da S, Sousa JBM de, Macedo G de S, Soares IM, Marchezini JL da C, Buna S dos SS, Martins KO, Andrade BC de M, Peixoto ELO, Leite LDF, Vieira SC, Oliveira MC de, Santos CCT. Diagnóstico de câncer de próstata em uma análise de incidência nos estados da Bahia e Rio Grande do Norte: houve influência do COVID-19? Res Soc Dev 2022; 11: e59711226285–e59711226285.

Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. The Prostate 2011; 71: 1054–1063.

Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006; 103: 14068–14073.

Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol 2021; 15: 790–800.

Chowdhury-Paulino IM, Ericsson C, Vince R, Spratt DE, George DJ, Mucci LA. Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis 2022; 25: 397–402.

Braga SFM, Souza MC de, Oliveira RR de, Andrade EIG, Acurcio F de A, Cherchiglia ML. Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System. Rev Saúde Pública; 51. Epub ahead of print 15 May 2017. DOI: 10.1590/S1518-8787.2017051006766.

Silva GA e, Jardim BC, Ferreira V de M, Junger WL, Girianelli VR. Mortalidade por câncer nas capitais e no interior do Brasil: uma análise de quatro décadas. Rev Saúde Pública 2020; 54: 126–126.